Shay Capital’s Viking Therapeutics VKTX Stock Holding History

Shay Capital’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.02M	Buy	31,400 +5,400	+21%	+$174K	0.09%	173
2025 Q4	$915K	Sell	26,000 -6,000	-19%	-$213K	0.09%	196
2025 Q3	$841K	Sell	32,000 -66,800	-68%	-$1.99M	0.07%	200
2025 Q2	$2.62M	Buy	98,800 +13,800	+16%	+$363K	0.3%	59
2025 Q1	$2.05M	Sell	85,000 -24,000	-22%	-$759K	0.3%	58
2024 Q4	$4.39M	Buy	109,000 +54,000	+98%	+$3.08M	0.67%	35
2024 Q3	$3.48M	Sell	55,000 -111,300	-67%	-$6.53M	0.49%	37
2024 Q2	$8.82M	Sell	166,300 -5,900	-3%	-$387K	1.22%	11
2024 Q1	$14.1M	Buy	+172,200	New	+$7.66M	2.2%	7

Other funds holding VKTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Shay Capital's VKTX Position: Q1 2026 in Review

Shay Capital opened a new position in Viking Therapeutics (VKTX) in Q1 2026: 16,500 shares worth $537K. The stake represents 0.04% of the portfolio and ranks #262 among its holdings. This is a return to the name: Shay Capital previously reported a position in VKTX as recently as Q2 2025.

Shay Capital first reported a position in VKTX in Q2 2023 and has held it in 8 quarters since. The position peaked at $2.5M in Q2 2024. 410 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

Shay Capital held 16,500 shares of Viking Therapeutics worth $537K as of Q1 2026.
Viking Therapeutics was a new Shay Capital position in Q1 2026.
Viking Therapeutics made up 0.04% of Shay Capital's portfolio in Q1 2026, its #262 holding.
Shay Capital first reported a position in Viking Therapeutics in Q2 2023 and has held it in 8 quarters since.
Shay Capital's Viking Therapeutics position peaked at $2.5M in Q2 2024.
410 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on Shay Capital's 13F filing for Q1 2026, filed 15 May 2026.